SteelPeak Wealth LLC Acquires Shares of 2,367 Natera, Inc. $NTRA

SteelPeak Wealth LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,367 shares of the medical research company’s stock, valued at approximately $473,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Robinhood Asset Management LLC purchased a new position in shares of Natera during the fourth quarter valued at about $12,981,000. Systrade AG purchased a new stake in shares of Natera in the fourth quarter worth about $11,454,000. J. Safra Sarasin Holding AG purchased a new stake in shares of Natera in the fourth quarter worth about $2,825,000. UBS Group AG boosted its stake in Natera by 19.4% during the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after buying an additional 71,355 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Natera by 25.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company’s stock valued at $11,476,000 after buying an additional 9,424 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider directly owned 142,295 shares in the company, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 178,872 shares of company stock worth $39,627,696. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

Shares of NTRA stock opened at $271.39 on Friday. The company has a market cap of $38.87 billion, a PE ratio of -166.50 and a beta of 1.51. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The stock’s 50 day simple moving average is $233.97 and its two-hundred day simple moving average is $220.41.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NTRA shares. Barclays reduced their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 24th. JPMorgan Chase & Co. raised their target price on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target on the stock. Morgan Stanley upped their price target on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.